Live Cell Integrated Surface Plasmon Resonance BiosensingApproach to Mimic the Regulation of Angiogenic Switch upon Anti-CancerDrug Exposure
Date of this Version
In this work, we report a novel surface plasmon resonance (SPR) based live-cell biosensing platform to measure and compare the binding affinity of vascular endothelial growth factor (VEGF) to vascular endothelial growth factor receptor (VEGFR) and VEGF to bevacizumab. Results have shown that bevacizumab binds VEGF with a higher association rate and affinity compared to VEGFR. Further, this platform has been employed to mimic the in vivo condition of the VEGF?VEGFR angiogenic switch. Competitive binding to VEGF between VEGFR and bevacizumab was monitored in real-time using this platform. Results demonstrated a significant blockage of VEGF?VEGFR binding by bevacizumab. From the results, it is evident that the proposed strategy is simple and highly sensitive for the direct and real-time measurements of bevacizumab drug efficacy to the VEGF?VEGFR angiogenic switch in living SKOV-3 cells.
Originally Published In
Liu, Chang; Alwarappan, Subbiah; Badr, Haitham A.; Zhang, Rui; Liu, Hongyun; Zhu, Jun-Jie; and Li, Chen-Zhong, "Live Cell Integrated Surface Plasmon Resonance BiosensingApproach to Mimic the Regulation of Angiogenic Switch upon Anti-CancerDrug Exposure" (2014). All Faculty. 79.
In Copyright - Non-Commmercial Use Permitted. URI: http://rightsstatements.org/vocab/InC-NC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. In addition, no permission is required from the rights-holder(s) for non-commercial uses. For other uses you need to obtain permission from the rights-holder(s).
This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.